Evaluation of a variant in the transcription factor 7‐like 2 (TCF7L2) gene and prostate cancer risk in a population‐based study

Publisher Website
Google Scholar
Abstract
Background: Transcription factor 7‐like 2 (TCF7L2) is a high mobility group‐box containing protein that is a critical member of the Wnt/β‐catenin canonical signaling pathway. In addition to its recently recognized role in diabetes, aberrant TCF7L2 expression has been implicated in cancer through regulation of cell proliferation and apoptosis by c‐MYC and cyclin D. It has been hypothesized that germline variants within the TCF7L2 gene previously associated with diabetes may affect cancer risk through the Wnt/β‐catenin signaling pathway. Specifically, the same risk allele of single nucleotide polymorphism (SNP) rs12255372 that is associated with diabetes (T allele) has recently been associated with an increased risk of breast cancer.Methods: Here, we investigated associations between rs12255372 and prostate cancer risk among 1,457 cases and 1,351 controls from a population‐based study.Results: The variant TT genotype was not associated with overall prostate cancer risk. However, there was evidence that men homozygous for the variant T allele had an elevated relative risk of more aggressive prostate cancer, as defined by high Gleason score (OR = 1.7, 95% CI = 1.0–2.8) or regional/distant stage (OR = 1.7, 95% CI = 1.1–2.6) disease.Conclusions: Our findings suggest that this variant in the TCF7L2 gene may be associated with risk of developing more clinically significant disease. These results need to be confirmed, but provide initial evidence that the TCF7L2 gene may alter risk of developing more aggressive prostate cancer. Prostate 68: 740–747, 2008.
Funding Information
  • National Cancer Institute (R01 CA56678, RO1 CA82664, RO1 CA092579)
  • Fred Hutchinson Cancer Research Center
  • National Human Genome Research Institute

This publication has 41 references indexed in Scilit: